Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas - Share buy-back programme of up to DKK 1,500m (approx. EUR 200m)

Vestas Wind Systems A/S, Aarhus, 15 August 2018                                                                                                         Company announcement No. 28/2018 Share buy-back programme of up to DKK 1,500m (approx. EUR 200m) The Board of Directors of Vestas Wind Systems A/S has decided to initiate a share buy-back programme of up to DKK 1,500m (approx. EUR 200m) to be executed during the period 15 August 2018 to 28 December 2018. The share buy-back programme is initiated pursuant to the authorisation granted to the Board of Directors by the annual general

Vestas - Interim financial report, second quarter 2018

Summary: Revenue on par with last year’s second quarter while earnings and free cash flow decreased. Solid order intake and combined order backlog at high level. Guidance for 2018 narrowed.  In the second quarter of 2018, Vestas generated revenue of EUR 2,260m – an increase of 2 percent compared to the year-earlier period. EBIT decreased by EUR 20m to EUR 259m. The EBIT margin was 11.5 percent compared to 12.6 percent in the second quarter of 2017 and free cash flow* amounted to EUR (173)m compared to EUR (158)m in the second quarter of 2017. The intake of firm and unconditional wind

Coloreel recruits from large international company

Coloreel continues to grow and now strengthens the company with recruitment from the international company ABB. New in the team is Benny Jonsson who is appointed as Vice President of Supply Chain from August."It feels amazing! Coloreel is an extremely exciting company with huge potential and it's extra fun to be apart of building the company at such an early stage, says Benny Jonsson", new Vice President of Supply Chain at Coloreel. Benny Jonsson is 44 years old and his latest employer was ABB in Västerås, where he worked as Production Manager. He has a broad background in production and

Bambuser AB (publ) publishes H1 2018

First 6 months – a restart for Bambuser January – June 2018 • Net sales amounted to 2,317 KSEK (3,468) • Total income amounted to 2,746 KSEK (5,279) • EBIT was -10,803 KSEK (-9,740) • Net income was -10,935 KSEK (-7,848) • Earnings per share of -0.72 SEK (-0.52) • Cash flow from operating activities was -10,850 KSEK (-5,642) • Cash at end of period was 16,273 KSEK (36,461)CEO Maryam Ghahremani comments: After assuming the position as Interim CEO of Bambuser March, 2018, with the mission to review the product and increase the short term revenues, I started working

New Australian patent approval for Episurf Medical

The Australian patent office IP Australia has announced that Episurf Medical (NASDAQ: EPIS B) has obtained another granted patent in Australia. The patent, entitled “Design method of a rig”, is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant. "I’m happy to see how the Episealer® Femoral Twin technology is getting backed up by a strong patent coverage globally”, comments Pål Ryfors, CEO, Episurf Medical. For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69

Interim report January – June 2018

Click here  to watch the quarterly video with CEO Jonas Tellander and CFO Sofie Zettergren. For the full report see attached pdf.Highlights from Q2 2018 report · Subscriber base up 47% Y/Y to 621 200, on track to reach 800 000 in 2018 · Streaming sales up 43% Y/Y to 239 MSEK, on track to reach 1 000 MSEK in 2018 · International streaming sales now 47% of total, on track to surpass 50% in 2018 · Storytel launched in the UAE, Turkey and Italy · E-book reading device (Storytel Reader) launched at the end of June ·

WntResearch and Biovica in Foxy-5 biomarker collaboration

Biovica International AB (publ) have agreed to collaborate with WntResearch AB regarding a biomarker for Foxy-5 treatment. The objective of the research is to deliver a companion diagnostic, a biomarker, coupled with Foxy-5.Biovica and WntResearch acknowledge the possibility to utilize a blood sample to identify patients that will benefit from Foxy-5. The rationale for the collaboration are several studies demonstrating that thymidine kinase (TK) activity can be measured with high precision by Biovicas DiviTumÒassay and is strongly correlated to tumor aggressiveness. To investigate the

Journal of Clinical Oncology publishes that IMMray™ PanCan-d serum biomarker test detects early pancreatic cancer with 96% accuracy

LUND, SWEDEN ― Immunovia AB announced today that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical validation study performed by Scandinavian and US researchers, showing that the IMMray™ PanCan-d serum biomarker microarray detects early pancreatic cancer with 96% accuracy.Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of <10% because of diffuse symptoms leading to late-stage diagnosis. It is widely accepted that that survival could increase significantly if localized tumors could be detected

BAKKAFROST: Invitation to Presentation/Webcast of Q2 2018 results 21 August 2018 at 8:00 am (CET)

Q2 2018 PRESENTATION A presentation of Bakkafrost’s interim report Q2 2018 will be held at 8:00 am (CET) on 21 August 2018 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway. WEBCAST The presentation will be transmitted live on Bakkafrost's website www.bakkafrost.com. Bakkafrost´s interim report Q2 2018 and presentation will be released prior to market opening on 21 August 2018 at 6:00 am (CET). Contacts: Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) Gunnar Nielsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the

Interim report – Second quarter and first half-year of 2018

Attached please find the full interim report as PDF file.________________________________________________________________________________ Announcement no. 1115 August 2018 Today, the Board of Directors approved the interim report for the second quarter and first half-year of 2018. The report contains the following highlights: ResultsAdjusted Result* for Q2 2018: USD 4 million (Q2 2017: USD -3 million)• Dry Operator: USD 8 million• Dry Owner: USD 3 million• Tankers: USD -8 million (USD 3 million)EBIT Q2 2018: USD 8 million (USD -3 million) * ”Profit/loss for the

Study of depression and efficacy of treatment published with promising results and in line with the National Board of Health and Welfare guidelines

The study has focused on both being able to detect depression in patients but also to look at the effect of treatment in the form of medication with Citalopram. The study shows that SensoDetect BERA can discern with a high statistical significance of patients with depression and already after about 1 week discern the effect of treatment which is unique and completely in line with the National Board of Health and Welfare stated improvement goals.The study is an important part of the development that SensoDetect works with for both tests for initial assessment of mental ill-health and for the

Double Bond Pharmaceutical manufactures first GMP batch of SI053

Double Bond Pharmaceuticals contract manufacturer of SI053 reports that they have successfully manufactured the first GMP batch. The batch is to be used among other things for the stability study for SI053. “There is a lot of work behind this batch and we are very pleased to be able to start the stability study according to plan” says Charlotte Karlsson, Quality Assurance Manager and coordinator of the manufacturing projects. “Getting a material for future clinical trials is an important milestone in the drug development process” commented Igor Lokot, CEO of Double Bond Pharmaceutical.

AstraZeneca prices a $3bn bond issue

15 August 2018 07:00 BST AstraZeneca prices a $3bn bond issue AstraZeneca PLC announces that, on 14 August 2018, it priced a four tranche global bond offering totalling $3bn. The offering is expected to close on 17 August 2018, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes, which may include the refinancing of existing indebtedness. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following four tranches: · $0.85bn of fixed

Invitation to presentation of AcadeMedia's full year result for July - June 2017/18

AcadeMedia's full year result for July - June 2017/18 will be published at 08:00 CET on August 29. A web-cast telephone conference will be held at 09:30 CEST the same day, where CEO Marcus Strömberg and CFO Eola Änggård Runsten will present the report. The presentation will be held in English and can be followed on the web or over the phone. It will be followed by a Q&A session. To participate in the conference call, and thereby be able to ask questions, call one of the following numbers ten minutes before the start of the call:UK: +442030089806SE: +46856642662US: +18557532235

PROGRESS IN FOCUS AREA MOBILE

INTERIM REPORT FOR THE PERIOD JANUARY TO JUNE 2018SECOND QUARTER  · Net sales for the remaining operation totaled SEK 18.7 (20.1) million. · The operating profit/loss for the remaining operation for the quarter totaled SEK -3.3 (0.5) million. · The profit/loss for the period for the remaining operation totaled SEK -4.1 (0.2) million. · Earnings per share for the remaining operation totaled SEK -0.01 (0.00). · Earnings per share for the total operation totaled SEK -0.01 (0.00). · Cash flow from total operating activities totaled SEK -8.6 (-1.3) million.

Stora Enso invests in building a Competence Centre and diversifying the raw material base for biocomposites

STORA ENSO OYJ INVESTOR NEWS 15 August 2018 at 9.00 EESTIn order to meet increasing customer demand, Stora Enso will broaden its biocomposites raw material base at the Hylte Mill, Sweden to provide more choice in technical properties and selection of fibres. The investment covers a new Biocomposites Competence Centre and the installation of new machinery for the milling of large fibres for the DuraSense™ by Stora Enso biocomposite material. “As we see an increasing demand for the innovative DuraSense™ biocomposite, the diversification of the raw material base and the new Biocomposites

BIMobject AB: Interim Report April - June 2018

Second quarter 2018 · Billing increased by 83 percent to SEK 33 (18) million. · The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. · The gross margin increased to 86 (81) percent. · The Group's operating profit improved to SEK -15 (-17) million. · Basic earnings per share amounted to SEK -0.29 (-0.31). · Cash flow from operating activities was SEK -18 (-15) million. · The accumulated number of users increased to approximately 845,000. · The

Hexagon Composites ASA: Results for the second quarter and first half year 2018

In the second quarter 2018 Hexagon Composites generated NOK 366.8 (372.0) million in revenue and made an operating profit before depreciation (EBITDA) of NOK 73.6 (47.8) million. Operating profit (EBIT) was NOK 54.3 (29.1) million and profit/loss before tax came to NOK 69.0 (18.0) million. Operating results in the second quarter were impacted positively by continued strong sales volumes within Hexagon Ragasco LPG and improved volumes within Hexagon Mobile Pipelines compared to same quarter last year. The EBITDA for the quarter includes a positive impact of NOK 40 million relating to a

Nel ASA: Invitation to presentation of Q2 2018 results

(Oslo, 15 August 2018) Nel ASA (Nel) will announce its second quarter 2018 report on Thursday 23 August at 07:00 CET and will host an open presentation at 08:00 CET.  Location: Hotel Continental, Oslo, Norway Time: 23 August 2018 at 08:00 CET Presenter: Jon André Løkke, CEO Nel ASA Language: English  The presentation will be broadcasted live at www.nelhydrogen.com and can also be viewed at http://webtv.hegnar.no/presentation.php?webcastId=92032306     The second quarter 2018 report and presentation will be made available through www.newsweb.no  and www.nelhydrogen.com.

Monobank ASA: MONO-ME Solid growth and improved profitability

· Loan growth of 12% in the quarter to a net loan balance of NOK 3 212 million · Net interest income of NOK 81.7million, up 19% from Q1 2018 (NOK 68.8 million) · Net profit after tax reached NOK 13.8 million, up 37% from Q1 2018 (NOK 10.0 million) · Successful launch of Monobank's unique and innovative credit card platform, a combined credit card and mobile payment app in late May · Geographical expansion continues; quarterly loan growth mainly driven by Finland · Euro denominated deposits from Germany, Austria, France and Spain through Raisin, a German online deposit

Targovax ASA: Invitation to second quarter and first half year 2018 results presentation Thursday 23 August

Oslo, Norway, 15 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET. Presentation The presentation will take place at 10:00 CET at: Hotel ContinentalStortingsgaten

Clas Ohlson increase sales in July

Sales in July increased by 7 per cent compared with July last year, corresponding to a sales increase of 3 per cent in local currencies. Clas Ohlson’s online sales growth in July amounted to 32 per cent.July sales increased by 7 per cent to 658 MSEK (616). In local currencies, sales increased by 3 per cent compared with the preceding year. Sales in July in comparable units and local currency decreased by 2 per cent. Online sales in July increased by 32 per cent to 19 MSEK (15). Compared with July last year, the store portfolio was expanded net by 14 stores. At the end of the period,

Asetek – Q2 2018: Record quarterly revenue

· Record quarterly and first-half revenue driven by high-end gaming cooling demand · Q2 revenue growth of 75% reflecting increased DIY sales · Q2 data center revenue fueled by OEM shipments · ASUS selects Asetek’s newest generation design for its first liquid coolers · 2018 desktop revenue growth expectation of between 15% to 25%Asetek reported revenue of $19.5 million in the second quarter of 2018, a 75% increase from the second quarter of 2017. First-half 2018 revenue amounted to $33.4 million, representing growth of 48% compared with the first half of 2017. The change from

There are no items matching the current filter
There are no more items matching the current filter
Back to top